Shares of Regeneron Pharmaceuticals (NASDAQ: REGN), a biotech giant, have been southbound over the past two years as the ...

As medical students, we hope for a future where fewer of our patients suffer from preventable tobacco-related illness. A ...

Roche (RHHBY) is upgraded to Buy as strong 2025 growth, new drug launches, and obesity drug potential create an attractive ...

Non-Cystic Fibrosis Bronchiectasis Treatment Market to Reach USD 3.5 Bn by 2035 at 5.8% CAGR, Driven by rising disease burden ...

A monthly injection has helped 90% of severe asthma patients reduce daily steroid tablets, which are associated with ...

The 2026 version of the Global Initiative for Chronic Obstructive Lung Disease (GOLD) strategy report has been published. Key ...

On November 17, 2025 Formycon AG (“Formycon”) announced development of a dupilumab biosimilar, FYB208, referencing Regeneron and Sanofi’s ...

University of Houston researchers developed a new X-ray imaging method capable of revealing hidden features in a single shot, ...

Fisher & Paykel is well-positioned to benefit from long-term growth prospects in hospital and home respiratory care. Increasing adoption of nasal high flow, or NHF, therapy in the hospital division is ...

Background Current guidelines for the evaluation of chronic obstructive pulmonary disease (COPD) do not recommend screening ...

The GOLD COPD Update 2026 provides updated guidance on case-finding, disease activity, exacerbation management.

Tecelra is the first engineered cell therapy for the treatment of certain patients with advanced synovial sarcoma. One year ...